Share on StockTwits

Cleveland BioLabs (NASDAQ:CBLI) was downgraded by Oppenheimer from an “outperform” rating to a “market perform” rating in a research note issued on Friday, reports. They currently have a $1.13 price objective on the stock, up from their previous price objective of $0.75. Oppenheimer’s price objective would indicate a potential upside of 63.79% from the stock’s previous close.

Cleveland BioLabs (NASDAQ:CBLI) traded down 8.01% on Friday, hitting $0.6899. 2,341,766 shares of the company’s stock traded hands. Cleveland BioLabs has a one year low of $0.63 and a one year high of $2.28. The stock has a 50-day moving average of $1.14 and a 200-day moving average of $1.46. The company’s market cap is $31.2 million.

Cleveland BioLabs (NASDAQ:CBLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.14) by $0.05. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.61 million. On average, analysts predict that Cleveland BioLabs will post $-0.49 earnings per share for the current fiscal year.

Cleveland BioLabs, Inc (NASDAQ:CBLI), incorporated on June 5 2003, is a biotechnology company focused on developing biodefense, tissue protection and cancer treatment drugs based on the concept of modulation of cell death for therapeutic benefit.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.